Similar articles

• [The ATAC study on adjuvants in breast cancer].

  Bravi S. Bravi S. Suppl Tumori. 2004 Jul-Aug;3(4):S15. Suppl Tumori. 2004. PMID: 15206200 Italian. No abstract available.
• [The ATAC study on adjuvants in breast cancer. What kind of repercussions will it have on clinical practice?].

  Gamucci T. Gamucci T. Suppl Tumori. 2004 Jul-Aug;3(4):S16. Suppl Tumori. 2004. PMID: 15206201 Italian. No abstract available.
• Preventive therapy for breast cancer: a consensus statement.

  Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H. Cuzick J, et al. Lancet Oncol. 2011 May;12(5):496-503. doi: 10.1016/S1470-2045(11)70030-4. Lancet Oncol. 2011. PMID: 21441069 Review.
• [National Conference of Medical Oncology. Controversies in the treatment of breast cancer. Genova, October 28, 2000].

  Longo F. Longo F. Tumori. 2000 Nov-Dec;86(6):A13-8. doi: 10.1177/030089160008600623. Tumori. 2000. PMID: 11271674 Italian. No abstract available.
• Is tamoxifen the Rosetta stone for breast cancer?

  Jordan VC. Jordan VC. J Natl Cancer Inst. 2003 Mar 5;95(5):338-40. doi: 10.1093/jnci/95.5.338. J Natl Cancer Inst. 2003. PMID: 12618491 Review. No abstract available.